Physician profile
David B Britt
NPI 1265424824
$15,638.35
in general payments reported to CMS, 2019-2025
50 companies · $1,541 in 2025
The $1,541 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $2,310 · 2021: $3,547 · 2022: $2,689 · 2023: $2,377 · 2024: $1,830 · 2025: $1,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,747.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,091.39 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $2,036.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,778.05 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,648.59 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $1,452.27 | 2019-2025 | |
| Lilly USA, LLC | $620.35 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $536.05 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $485.16 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $471.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $443.58 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $357.76 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $325.62 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $302.56 | 2019-2023 | |
| Indivior INC. | $299.05 | 2023-2025 | Sublocade |
| Amarin Pharma, INC. | $292.88 | 2019-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Britt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.